Beijing Aosaikang Pharmaceutical Co., Ltd. (SHE:002755)
China · Delayed Price · Currency is CNY 12.66
-0.13 (-1.02%)
Nov 6, 2026, 3:04 PM CST
SHE:002755 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 11,751 | 15,157 | 11,797 | 10,043 | 7,370 | 11,815 | |
Market Cap Growth | -33.54% | 28.48% | 17.47% | 36.27% | -37.63% | -2.53% |
Enterprise Value | 9,432 | 12,801 | 9,955 | 8,433 | 5,757 | 10,477 |
Last Close Price | 12.66 | 16.18 | 12.51 | 10.65 | 7.81 | 12.40 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 66.14 | 64.06 | 73.60 | - | - | 31.10 |
Forward PE | - | 85.95 | 231.09 | 15.30 | 15.30 | 15.30 |
PS Ratio | 7.38 | 8.52 | 6.64 | 6.96 | 3.94 | 3.80 |
PB Ratio | 3.51 | 4.63 | 3.75 | 3.34 | 2.45 | 3.66 |
P/TBV Ratio | 4.30 | 5.75 | 4.05 | 3.59 | 2.57 | 3.79 |
P/FCF Ratio | 95.12 | 29.83 | 65.20 | - | - | 27.23 |
P/OCF Ratio | 39.99 | 23.26 | 28.68 | - | - | 20.81 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 5.92 | 7.20 | 5.60 | 5.84 | 3.08 | 3.37 |
EV/EBITDA Ratio | 28.85 | 40.17 | 55.60 | - | - | 26.11 |
EV/EBIT Ratio | 56.42 | 66.38 | 105.29 | - | - | 33.83 |
EV/FCF Ratio | 76.35 | 25.20 | 55.02 | - | - | 24.14 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.02 | 0.04 | 0.02 | 0.00 |
Debt / EBITDA Ratio | 0.11 | 0.11 | 0.40 | - | - | 0.03 |
Debt / FCF Ratio | 0.29 | 0.07 | 0.40 | - | - | 0.03 |
Net Debt / Equity Ratio | -0.71 | -0.75 | -0.64 | -0.54 | -0.52 | -0.52 |
Net Debt / EBITDA Ratio | -7.38 | -7.68 | -11.29 | 7.84 | 6.94 | -4.17 |
Net Debt / FCF Ratio | -19.35 | -4.82 | -11.17 | 10.50 | 7.65 | -3.86 |
Asset Turnover | 0.36 | 0.42 | 0.47 | 0.42 | 0.53 | 0.83 |
Inventory Turnover | 2.47 | 2.20 | 1.83 | 1.80 | 1.73 | 1.78 |
Quick Ratio | 2.75 | 2.37 | 2.85 | 4.62 | 6.05 | 5.69 |
Current Ratio | 2.90 | 2.56 | 3.13 | 5.07 | 6.60 | 6.19 |
Return on Equity (ROE) | 5.65% | 6.66% | 4.18% | -6.89% | -8.53% | 12.16% |
Return on Assets (ROA) | 2.37% | 2.81% | 1.56% | -5.23% | -5.48% | 5.14% |
Return on Invested Capital (ROIC) | 13.54% | 16.73% | 6.43% | -20.51% | -20.79% | 18.50% |
Return on Capital Employed (ROCE) | 4.90% | 5.80% | 2.90% | -9.40% | -10.10% | 9.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.51% | 1.56% | 1.36% | -1.48% | -3.06% | 3.21% |
FCF Yield | 1.05% | 3.35% | 1.53% | -1.55% | -2.76% | 3.67% |
Dividend Yield | 0.95% | 0.73% | 0.94% | - | - | 0.79% |
Payout Ratio | 61.01% | 47.11% | 0.72% | - | - | 48.89% |
Buyback Yield / Dilution | 0.62% | -0.37% | -1.57% | 1.34% | -1.55% | -0.16% |
Total Shareholder Return | 1.57% | 0.36% | -0.63% | 1.34% | -1.55% | 0.63% |